Inhibition of Glycosaminoglycan-Mediated Amyloid Formation by Islet Amyloid Polypeptide and proIAPP Processing Intermediates

被引:17
作者
Meng, Fanling [1 ]
Raleigh, Daniel P. [1 ,2 ]
机构
[1] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Grad Program Biophys, Grad Program Biochem & Struct Biol, Stony Brook, NY 11794 USA
基金
美国国家卫生研究院;
关键词
IAPP; amylin; proIAPP; amyloid; prohormone; GENE-RELATED PEPTIDE; FIBRIL FORMATION; DIABETES-MELLITUS; ALZHEIMERS-DISEASE; BASEMENT-MEMBRANE; PANCREATIC-ISLETS; CLEAVAGE SITE; BETA-CELLS; HUMAN IAPP; PROTEIN;
D O I
10.1016/j.jmb.2010.12.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Islet amyloid polypeptide (IAPP; also known as amylin) is responsible for islet amyloid formation in type 2 diabetes, and IAPP-induced toxicity is believed to contribute to the loss of beta-cell mass associated with the late stages of type 2 diabetes. Islet amyloid formation may also play a role in graft failure after transplantation. IAPP is produced as a prohormone, pro-islet amyloid polypeptide (proIAPP), and processed in the secretory granules of the pancreatic beta-cells. Partially processed forms of proIAPP are found in amyloid deposits; most notable is a 48-residue intermediate, proIAPP(1-48), which includes the N-terminal pro-extension, but which has been properly processed at the C-terminus. Incomplete processing may play a role in islet amyloid formation by promoting interactions with sulfated proteoglycans of the extracellular matrix, which, in turn, promote amyloid formation. We show that acid fuchsin (3-(1-(4-amino-3-methyl-5-sulphonatophenyl)-1-(4-amino-3-sulphonatophenyl)methylene)cyclohexa-1,4-diene-sulphonic acid), a simple sulfonated triphenyl methyl derivative, is a potent inhibitor of amyloid formation by the proIAPP(1-48) intermediate. The more complicated triphenyl methane derivative fast green FCF {ethyl-[4-[[4-[ethyl-[(3-sulfophenyl)methyl]amino]phenyl]-(4-hydroxy-2-sulfophenyl) methylidene]-1-cyclohexa-2,5-dienylidene]-[(3-sulfophenyl)methyl]aza-nium} also inhibits amyloid formation by IAPP and the proIAPP processing intermediate. Both compounds inhibit amyloid formation by mixtures of the proIAPP intermediate and the model glycosaminoglycan heparan sulfate. Acid fuchsin also inhibits glycosaminoglycan-mediated amyloid formation by mature IAPP. The ability to inhibit amyloid formation is not simply due to the compounds being sulfonated, since the sulfonated inhibitor of amyloid-beta, tramiprosate, is not an inhibitor of amyloid formation by proIAPP(1-48). (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码:491 / 502
页数:12
相关论文
共 62 条
[1]   Recovery and purification of highly aggregation-prone disulfide-containing peptides: Application to islet amyloid polypeptide [J].
Abedini, A ;
Singh, G ;
Raleigh, DP .
ANALYTICAL BIOCHEMISTRY, 2006, 351 (02) :181-186
[2]   Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide [J].
Abedini, A ;
Raleigh, DP .
ORGANIC LETTERS, 2005, 7 (04) :693-696
[3]   A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor [J].
Abedini, Andisheh ;
Meng, Fanling ;
Raleigh, Daniel P. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (37) :11300-+
[4]   Characterization of the heparin binding site in the N-terminus of human pro-islet amyloid polypeptide: Implications for amyloid formation [J].
Abedini, Andisheh ;
Tracz, Sylvia M. ;
Cho, Jae-Hyun ;
Raleigh, Daniel P. .
BIOCHEMISTRY, 2006, 45 (30) :9228-9237
[5]   Amyloid Deposition in Transplanted Human Pancreatic Islets: A Conceivable Cause of Their Long-Term Failure [J].
Andersson, Arne ;
Bohman, Sara ;
Borg, L. A. Hakan ;
Paulsson, Johan F. ;
Schultz, Sebastian W. ;
Westermark, Gunilla T. ;
Westermark, Per .
EXPERIMENTAL DIABETES RESEARCH, 2008, :562985
[6]   Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles [J].
Blazer, Levi L. ;
Neubig, Richard R. .
NEUROPSYCHOPHARMACOLOGY, 2009, 34 (01) :126-141
[7]   Islets in Type 2 Diabetes: In Honor of Dr. Robert C. Turner [J].
Bonner-Weir, Susan ;
O'Brien, Timothy D. .
DIABETES, 2008, 57 (11) :2899-2904
[8]   β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].
Butler, AE ;
Janson, J ;
Bonner-Weir, S ;
Ritzel, R ;
Rizza, RA ;
Butler, PC .
DIABETES, 2003, 52 (01) :102-110
[9]   The Ability of Rodent Islet Amyloid Polypeptide To Inhibit Amyloid Formation by Human Islet Amyloid Polypeptide Has Important Implications for the Mechanism of Amyloid Formation and the Design of Inhibitors [J].
Cao, Ping ;
Meng, Fanling ;
Abedini, Andisheh ;
Raleigh, Daniel P. .
BIOCHEMISTRY, 2010, 49 (05) :872-881
[10]   Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation [J].
Castillo, GM ;
Cummings, JA ;
Yang, WH ;
Judge, ME ;
Sheardown, MJ ;
Rimvall, K ;
Hansen, JB ;
Snow, AD .
DIABETES, 1998, 47 (04) :612-620